Humacyte (HUMA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting commenced virtually with executive management, board members, and legal counsel present.
Voting procedures and eligibility were outlined, with polls open during the meeting.
Rules of conduct and question submission process were explained for stockholders.
Board and executive committee updates
Introduction of director nominees John P. Bamforth, Keith Anthony Jones, and Kathleen Sebelius for election as Class II directors until the 2029 annual meeting.
Board unanimously recommended voting in favor of all director nominees and proposals.
Shareholder proposals
Advisory vote on executive compensation and frequency of future Say-on-Pay votes presented.
Proposal to ratify PricewaterhouseCoopers LLP as independent auditor for 2026.
Proposal to amend certificate of incorporation to increase authorized common stock from 350 million to 550 million shares.
Latest events from Humacyte
- Symvess sales rose, net loss widened, restructuring cut costs, and global expansion progressed.HUMA
Q1 202613 May 2026 - 2025 revenue grew to $2.0M, net loss narrowed, and major clinical and commercial milestones achieved.HUMA
Q4 20251 May 2026 - ATEV outperformed AV fistula in women with ESKD, reducing catheter dependence and complications.HUMA
KOL event30 Apr 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and increasing authorized shares.HUMA
Proxy filing28 Apr 2026 - Board recommends approval of all proposals, including director elections and share increase.HUMA
Proxy filing17 Apr 2026 - Strong clinical data and strategic partnerships drive expansion into trauma, dialysis, and coronary markets.HUMA
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Engineered vessel platform shows clinical, economic, and pipeline momentum across major indications.HUMA
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - SYMVESS launch targets trauma centers with strong clinical data and a robust cash runway through 2026.HUMA
H.C. Wainwright 3rd Annual BioConnect Investor Conference 20253 Feb 2026 - Engineered vessels show superior outcomes in trauma, with FDA decision expected in August.HUMA
Jefferies 2024 Global Healthcare Conference1 Feb 2026